English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIn a new multicenter international study led by the Mayo Clinic Comprehensive Cancer Center, researchers found that people with the B-cell precursor subtype of acute lymphoblastic leukemia (BCP-ALL), who also lacked a genetic abnormality known as the Philadelphia chromosome and were in remission with no trace of cancer, showed significantly higher survival rates when blinatumomab was added to their chemotherapy treatment.
Tag: Cancer Research
NCCN Oncology Research Program Celebrates 25 Years of Advancing Cancer Science
The National Comprehensive Cancer Network (NCCN)’s research arm achieves major milestone, showcasing years of success in fostering innovation and knowledge discovery that improves the lives of patients with cancer.
Landmark Study Shows Elevated Cancer Risk for Women with Endometriosis
Women with endometriosis are four times more likely to develop ovarian cancer, and those with more severe cases are at an even greater risk.
Dr. Tanya Stoyanova receives $1.8 million to reveal new treatment strategies for advanced prostate cancer
Dr. Tanya Stoyanova, associate professor of molecular and medical pharmacology and urology at the David Geffen School of Medicine at UCLA(Link is external) (Link opens in new window), was awarded a $1.8 million grant from the National Cancer Institute to identify new drivers and test new therapeutic strategies for advanced treatment-resistant prostate cancer.
Cancer researchers receive grant to combat aggressive kidney cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) have received an $800,000 grant from the V Foundation to find new ways to treat and prevent a severe form of kidney cancer associated with a hereditary syndrome caused by mutations in the fumarate hydratase (FH) gene.
MD Anderson Research Highlights for July 11, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Call for Papers: Theme Issue: Artificial Intelligence in Oncology
JMIR Publications invites submissions to a new theme issue titled “Artificial Intelligence in Oncology” in its premier open access journal JMIR Bioinformatics and Biotechnology indexed in PubMed Central and PubMed, SCOPUS, Sherpa/Romeo, DOAJ and EBSCO/EBSCO Essentials.
SHRO Award Announcement June 28 2024
The annual Taobook International Literary Festival held in Taormina, Sicily has announced their 2024 Taobuk Awards, naming Professor Antonio Giordano, MD, PhD, President and Founder of the Sbarro Health Research Organization (SHRO), this year’s recipient of the Da Vinci Award.
Fred Hutch launches new scientific training program for high school and middle school teachers
Fred Hutch Cancer Center has launched (PS2@FH), a new summer research program that trains middle school and high school teachers in Fred Hutch labs to expand hands-on learning experiences they can take back to the classroom.
Researchers report first effective use of immunotherapy for most common subtype of colorectal cancer
These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination.
The Harvey L. Neiman Health Policy Institute Launches Cancer Equity Compass
The Harvey L. Neiman Health Policy Institute announces the public launch of a new online tool that reveals the overlap between cancer disparities and social determinants of health (SDOH) using advanced heat maps of U.S. counties. The Cancer Equity Compass can identify high-opportunity targets for policies and programs to achieve equitable health outcomes in underserved populations.
Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients
An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.
Pediatric brain tumors rely on different metabolic “route” to fuel treatment resistance
Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Roswell Park Comprehensive Cancer Center has earned its most highly rated grant from the National Cancer Institute (NCI). The NCI renewed Roswell Park’s status as a Comprehensive Cancer Center – a designation held by less than 4% of cancer centers- awarding Roswell Park the highest possible “Exceptional” rating as it renewed a grant Roswell Park has successfully competed for since 1972.
Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.
ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans
A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.
From Bench to Bedside on Ovarian Cancer
May 22nd marked a significant milestone in the collaborative efforts to combat ovarian cancer as the “International Dialogue on Ovarian Cancer, from Bench to Bedside” congress was held, bridging the gap between primary research and clinical practice.
Hearst Health Prize judging panel selects two finalists; Winner to be announced at UCLA Health Data Day
Hearst Health and the UCLA Center for SMART Health today announced that a panel of expert judges has selected Mount Sinai Health System and The University of Texas MD Anderson Cancer Center as the 2024 Hearst Health Prize finalists. The winner will be announced at UCLA Health Data Day on June 4, 2024.
Dr. Daniel Geynisman Named New Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network
Daniel M. Geynisman, MD, is being announced the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman, Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has a long history of working with NCCN in a variety of roles.
Wetter Recognized for Exemplary Leadership in Cancer Equity Initiatives
David Wetter, PhD, has been honored for pioneering cancer health equity strategies, transforming research into practical solutions, and fostering vital community partnerships for underserved populations and rural communities.
Interdisciplinary team of UWF faculty help write the rules on cancer prevention in Florida
UWF faculty, serving as evaluators for Florida’s Cancer Prevention and Control Program since 2018, recently had their contract renewed for $680,000 over four years due to excellent performance, as acknowledged by the CDC.
CHOP, Stanford Researchers Identify Protein That Controls CAR T Cell Longevity
CAR T cell therapy has revolutionized the way certain types of cancer are treated, and the longer those CAR T cells live in a patient’s body, the more effectively they respond to cancer. Now, researchers have found that a protein called FOXO1 improves the survival and function of CAR T cells, which may lead to more effective CAR T cell therapies and could potentially expand its use in difficult-to-treat cancers.
AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.
Penn Medicine at the AACR Annual Meeting 2024
Researchers from the Abramson Cancer Center (ACC) and Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in cancer science and medicine at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
HERSTORY: Democratizing cancer genetic testing to reduce healthcare disparities
HERSTORY is focused on understanding genetic, environmental, socio-economic, and other determinants of cancer in women with a family history of the disease.
Researcher’s microscale tech is chipping away at cancer, organ failure and neurological disease
For outstanding contributions to engineering of biomimetic tissue-on-chip technologies and organoids for disease modeling and regenerative medicine, ASU’s Mehdi Nikkhah has been inducted as a Fellow into the American Institute for Medical and Biomedical Engineering.
MD Anderson’s Institute for Data Science in Oncology announces appointment of inaugural IDSO Affiliates
MD Anderson’s Institute for Data Science in Oncology today announced the appointment of its inaugural cohort of 33 IDSO Affiliates, who bring diverse expertise to advance the work of the institute and foster the data science ecosystem at MD Anderson.
Starting STEM Earlier
The UNM Comprehensive Center is expanding a program aimed at encouraging young people to explore research as a career field. In addition to a first-ever middle school component, the program is adding more opportunities for high school and undergraduates to get real world lab and research experience.
Cancer Research in 3D
In cancer research, seeing is believing. Before they can diagnose or treat cancer, researchers and doctors need to have a clear understanding of what’s happening at a microscopic level. While existing technology allows us to see things the naked eye can’t, a team of researchers at the Department of Energy’s Oak Ridge National Laboratory (ORNL) is working to standardize a process for staining and seeing cancer in a whole new perspective – in 3D (three dimensions).
Less chemoradiation is possible for some cancer patients
Scaling back treatment can mean better quality of life for oropharynx cancer patients who qualify
Targeted drug shows promising ability in treating rare head and neck cancers
Experts at Rogel Cancer Center develop and study the impact of a new drug for salivary gland cancers
LJI welcomes new faculty member Miguel Reina-Campos, Ph.D.
Cancer researcher Miguel Reina-Campos, Ph.D., has joined the faculty of La Jolla Institute for Immunology (LJI) as an Assistant Professor to lead the Laboratory of Tissue Immune Networks. His laboratory at LJI aims to investigate the basis of CD8+ T cell tissue immunity to improve life-saving cancer immunotherapies.
Researchers uncover a potential genetic marker associated with better survival outcomes in patients with head and neck cancer
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center show for the first time that a gene usually linked to giant axonal neuropathy, a rare and severe neurological condition, also plays a role in inhibiting aggressive tumor cell growth in head and neck cancers.
Uniformed Services University to Represent DoD in New Cancer Screening Research Network
To identify cancers earlier and better understand when they may be easier to treat, the National Cancer Institute (NCI), part of the National Institutes of Health, has launched a new clinical trials network to evaluate emerging technologies for cancer screening.
Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial
An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.
UCLA-led research results in FDA approval of 4-drug combination for frontline treatment of metastatic pancreatic cancer
A four-drug chemotherapy regimen of irinotecan liposome (Onivyde) in combination with oxaliplatin, leucovorin, and fluorouracil has been approved by the FDA for the first-line treatment of metastatic pancreatic adenocarcinoma.
Clues to early onset colorectal cancer found in microbiome of Hispanic patients
Nina Sanford, M.D., Chief of Gastrointestinal Radiation Oncology Service, UT Southwestern Medical Center Most people have a screening colonoscropy around age 50, however recent research has uncovered a rise in early onset colorectal cancer in patients younger than 50. What can…
Immunotherapy before surgery leads to promising long-term survival in sarcoma patients
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center
Case Western Reserve University researcher awarded $2 million federal grant to further explore possible new effective treatments for colorectal and other cancers
With a new $2 million federal grant, a researcher with the Case Western Reserve University School of Medicine will lead a team to further explore preliminary findings of an effective treatment for colorectal and possibly other cancers.
Sara Federico, MD, named director of the Solid Tumor Division at St. Jude Children’s Research Hospital
Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.
Inaugural class of Damon Runyon–St. Jude Pediatric Cancer Research Fellows announced
The initiative aims to provide support for early-career scientists to study pediatric cancer, addressing a funding gap that drives top talent to seek more prevalent opportunities in adult cancer research or the pharmaceutical sector.
Scientists engineer potent immune cells for ‘off-the-shelf’ cancer immunotherapy
UCLA scientists have developed a new method to engineer more powerful immune cells that can potentially be used for “off-the-shelf” cell therapy to treat challenging cancers.
High biological age may increase the risk of dementia and stroke
People who have a higher biological age than their actual chronological age have an increased risk of stroke and dementia. The findings suggest that by slowing down the body’s aging processes, it may be possible to reduce or delay the onset of disease.
At the same PSA level, Black men are more likely to have prostate cancer than white men
Findings indicate the importance of earlier and more frequent prostate cancer screening for Black men.
Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation
The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.
Metabolite tells cells whether to repair DNA
Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.
Cancer Prevention and Research Institute of Texas Awards $7.5 Million to Baylor Scott & White Research Institute
Baylor Scott & White Research Institute will establish the Texas site of the Connect for Cancer Prevention StudyTM (Connect), a project of the National Cancer Institute (NCI), part of the National Institutes of Health. Nine healthcare systems plan to enroll 200,000 adults across the U.S.
The sunscreen paradox: McGill University researchers warn of ‘false sense of security’
Sunscreen is important, says Dr. Ivan Litvinov, but it is also the least effective way to protect your skin when compared to sun protective clothing and sun avoidance
Antibody-drug conjugate helps patients with metastatic non-small cell lung cancer live longer, delaying disease progression
Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.